Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
UCB is currently updating its Investor Relations contact database, so as to enhance its communication flow. In the context of a new Investor Relations database management system, it has been...
-
UCB is currently updating its Investor Relations contact database, so as to enhance its communication flow. In this context, we kindly invite you to fill out the attached form using the...
-
Dear Madam, Dear Sir, UCB will present the first detailed Phase III Clinical Study Results of Cimzia(TM) for the treatment of Crohn's disease (PRECISE 2) at the United European...
-
-
Dear Madam, Dear Sir, UCB will present the first detailed Phase III Clinical Study Results of Cimzia(TM) for the treatment of Crohn's disease (PRECISE 2) at the United European...
-
Dear Madam, Dear Sir, UCB will present the first detailed Phase III Clinical Study Results of Cimzia(TM) for the treatment of Crohn's disease (PRECISE 2) on Tuesday October 18, 2005 in...
-
BRUSSELS, Belgium, Sept. 22, 2005 (PRIMEZONE) -- Today UCB announced that the European Commission has approved the use of Keppra(r) (levetiracetam) in the European Union, as adjunctive therapy in the...
-
Brussels, BELGIUM - September 22, 2005 - Today UCB announced that the European Commission has approved the use of Keppra® (levetiracetam) in the European Union, as adjunctive therapy in the treatment...
-
Bruxelles, BELGIQUE - le 22 septembre 2005 - UCB a annoncé aujourd'hui que la Commission européenne a approuvé l'utilisation du Keppra® (lévétiracétam) au sein de l'Union européenne, en tant que...
-
Brussel, BELGIË - 22 september 2005 - UCB heeft vandaag meegedeeld dat de Europese Commissie het gebruik van Keppra® (levetiracetam) in de Europese Unie heeft goedgekeurd als hulptherapie bij de...